ChIP-Seq for HOXB13 in LNCaP cell line with GSK treatment and VEH control. ChIP-Seq for HOXB13 in LNCaP cell line with GSK treatment and VEH control

We show in prostate cancer cells that LSD1 co-localizes with FOXA1 and active enhancer markers, and that LSD1 inhibition globally disrupts FOXA1 chromatin binding. Overall design: ChIP-Seq of HOXB13 was performed in LNCaP cells treated with vehicle or GSK2879552

本研究在前列腺癌细胞中证实，赖氨酸特异性去甲基化酶1（LSD1）可与叉头框蛋白A1（FOXA1）及活性增强子标记物发生共定位，且抑制LSD1可全局性破坏FOXA1的染色质结合能力。实验总体设计：本研究在经溶剂对照或GSK2879552处理的LNCaP细胞系中，开展了同源盒B13（HOXB13）的染色质免疫共沉淀测序（ChIP-Seq, Chromatin Immunoprecipitation Sequencing）实验。